Cancer Research and Treatment

Original Articles

The Survival and Financial Benefit of Investigator-Initiated Trials Conducted by Korean Cancer Study Group: Bum Jun Kim, Chi Hoon Maeng, Bhumsuk Keam, Young-Hyuck Im, Jungsil Ro, Kyung Hae Jung, Seock-Ah Im, Tae Won Kim, Jae Lyun Lee, Dae Seog Heo, Sang-We Kim, Keunchil Park, Myung-Ju Ahn, Byoung Chul Cho, Hoon-Kyo Kim, Yoon-Koo Kang, Jae Yong Cho, Hwan Jung Yun, Byung-Ho Nam, Dae Young Zang; Received April 30, 2024 Accepted July 8, 2024 Published online July 10, 2024; DOI: https://doi.org/10.4143/crt.2024.421 [Epub ahead of print]

Abstract PDF PubReader ePub: Purpose
The Korean Cancer Study Group (KCSG) is a nationwide cancer clinical trial group dedicated to advancing investigator-initiated trials (IITs) by conducting and supporting clinical trials. This study aims to review IITs conducted by KCSG and quantitatively evaluate the survival and financial benefits of IITs for patients.
Materials and Methods
We reviewed IITs conducted by KCSG from 1998 to 2023, analyzing progression-free survival (PFS) and overall survival (OS) gains for participants. PFS and OS benefits were calculated as the difference in median survival times between the intervention and control groups, multiplied by the number of patients in the intervention group. Financial benefits were assessed based on the cost of investigational products provided.
Results
From 1998 to 2023, KCSG conducted 310 IITs, with 133 completed and published. Of these, 21 were included in the survival analysis. The analysis revealed that 1,951 patients in the intervention groups gained a total of 2,558.4 months (213.2 years) of PFS and 2,501.6 months (208.5 years) of OS, with median gains of 1.31 months in PFS and 1.58 months in OS per patient. When analyzing only statistically significant results, PFS and OS gain per patients was 1.69 months and 3.02 months, respectively. Investigational drug cost analysis from six available IITs indicated that investigational products provided to 252 patients were valued at 10,400,077,294 won (approximately 8,046,481 US dollars), averaging about 41,270,148 won (approximately 31,930 US dollars) per patient.
Conclusion
Our findings, based on analysis of published research, suggest that IITs conducted by KCSG led to survival benefits for participants and, in some studies, may have provided financial benefits by providing investment drugs.

661 View
45 Download

Genitourinary cancer

Clinical Outcomes of Small Cell Carcinoma of the Genitourinary Tract and the Prognostic Significance of the Tumor Immune Microenvironment: Jaewon Hyung, Hyung-Don Kim, Gi Hwan Kim, Yong Mee Cho, Yeon-Mi Ryu, Sang-Yeob Kim, Inkeun Park, Shinkyo Yoon, Jae Lyun Lee; Cancer Res Treat. 2024;56(2):624-633. Published online November 29, 2023; DOI: https://doi.org/10.4143/crt.2023.1076

Abstract PDF Supplementary Material PubReader ePub: Purpose
Small cell carcinoma of the genitourinary tract (GU SCC) is a rare disease with a poor prognosis. There are only limited treatment options due to insufficient understanding of the disease. In this study, we analyzed the clinical outcomes of patients with GU SCC and their association with the tumor immune phenotype.
Materials and Methods
Patients diagnosed with GU SCC were included. Survival outcomes according to the primary location (prostate and non-prostate) and stages (limited disease [LD] and extensive disease [ED]) were analyzed. We performed multiplex immunohistochemistry (IHC) in non-prostate SCC patients and analyzed the immune cell population.
Results
A total of 77 patients were included in this study. Their median age was 71 years, 67 patients (87.0%) were male, and 48 patients (62.3%) had non-prostate SCC. All patients with ED (n=31, 40.3%) received etoposide plus platinum (EP) as initial treatment and median overall survival (OS) was 9.7 months (95% confidence interval [CI], 7.1 to 18.6). Patients with LD (n=46, 59.7%) received EP followed by radiotherapy or surgery, and 24-months OS rate was 63.6% (95% CI, 49.9 to 81.0). The multiplex IHC analysis of 21 patients with non-prostate SCC showed that patients with a higher density of programmed death-ligand 1–expressing CD68+CD206+ M2-like macrophages had significantly worse OS outcomes with an adjusted hazards ratio of 4.17 (95% CI, 1.25 to 14.29; adjusted p=0.02).
Conclusion
Patients with GU SCC had a poor prognosis, even those with localized disease. The tumor immune phenotypes were significantly associated with survival. This finding provides new insights for treating GU SCC.

2,928 View
123 Download

Real-World Study Evaluating Safety and Effectiveness of Axitinib in Korean Patients with Renal Cell Carcinoma after Failure of One Prior Systemic Therapy: Sang Joon Shin, Jae Lyun Lee, Tae Gyun Kwon, Byoung Young Shim, Ho Seok Chung, Sang-Hee Kim, Se Hoon Park; Cancer Res Treat. 2023;55(2):643-651. Published online November 28, 2022; DOI: https://doi.org/10.4143/crt.2022.883

Abstract PDF Supplementary Material PubReader ePub

Purpose
This post-marketing surveillance (PMS) study was conducted to monitor the usage of axitinib (Inlyta) in clinical practice of Korean patients with advanced renal cell carcinoma (RCC) with disease progression during or after a prior systemic therapy in real world.
Materials and Methods
In this multicenter, observational study, patients indicated for oral axitinib 5 mg twice daily as second-line therapy for advanced RCC were followed up under routine clinical practices, and their safety and effectiveness outcomes were collected.
Results
Between 2012 and 2021, 125 patients were enrolled, and data from 111 patients were analyzed. Median age was 65 years (range, 30 to 84 years), 81% was male, and 110 (99%) had clear cell RCC. The median daily dose of axitinib was 10 mg (range, 4.36 to 15.95 mg) with a median administration period of 5.6 months (range, 15 to 750 days). Eighty-three percentage of patients experienced any grade of adverse events, 71% of which were related to study treatment, including diarrhea (36%), hypertension (21%), stomatitis (17%), decreased appetite (14%), palmar-plantar erythrodysesthesia syndrome (12%), and asthenia (11%). Most adverse events were generally well tolerated and manageable, with 13% of grade ≥ 3. Axitinib dose reduction was required in 20% of the adverse events and discontinuation in 8%. Median progression-free survival was 12.4 months (95% confidence interval [CI], 9.6 to 18.9). Objective responses were observed in 30% of patients (95% CI, 21 to 39) with 4% of complete response and 26% of partial response.
Conclusion
No new safety signal was found in the present PMS study of Korean RCC patients. Axitinib showed consistent outcomes in terms of effectiveness and safety confirming that the drug is a valid option for second-line therapy in patients with advanced RCC in a real-world setting.

Citations

Citations to this article as recorded by

Axitinib

Reactions Weekly.2024; 1991(1): 45. CrossRef

4,572 View
159 Download
1 Crossref

The Prognosis and the Role of Adjuvant Chemotherapy for Node-Positive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by Surgery: Hyehyun Jeong, Kye Jin Park, Yongjune Lee, Hyung-Don Kim, Jwa Hoon Kim, Shinkyo Yoon, Bumsik Hong, Jae Lyun Lee; Cancer Res Treat. 2022;54(1):226-233. Published online May 6, 2021; DOI: https://doi.org/10.4143/crt.2021.365

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aims to evaluate the prognosis of pathologically node-positive bladder cancer after neoadjuvant chemotherapy, the role of adjuvant chemotherapy in these patients, and the value of preoperative clinical evaluation for lymph node metastases.
Materials and Methods
Patients who received neoadjuvant chemotherapy followed by partial/radical cystectomy and had pathologically confirmed lymph node metastases between January 2007 and December 2019 were identified and analyzed.
Results
A total of 53 patients were included in the study. The median age was 61 years (range, 34 to 81 years) with males comprising 86.8%. Among the 52 patients with post-neoadjuvant/pre-operative computed tomography results, only 33 patients (63.5%) were considered positive for lymph node metastasis. Sixteen patients (30.2%) received adjuvant chemotherapy (AC group), and 37 patients did not (no AC group). With the median follow-up duration of 67.7 months, the median recurrence-free survival (RFS) and the median overall survival (OS) was 8.5 months and 16.2 months, respectively. The 2-year RFS and OS rates were 23.3% and 34.6%, respectively. RFS and OS did not differ between the AC group and no AC group (median RFS, 8.8 months vs. 6.8 months, p=0.772; median OS, 16.1 months vs. 16.3 months, p=0.479). Thirty-eight patients (71.7%) experienced recurrence. Distant metastases were the dominant pattern of failure in both the AC group (91.7%) and no AC group (76.9%).
Conclusion
Patients with lymph node-positive disease after neoadjuvant chemotherapy followed by surgery showed high recurrence rates with limited survival outcomes. Little benefit was observed with the addition of adjuvant chemotherapy.

Citations

Citations to this article as recorded by

A Predictive Nomogram for Development of Lymph Node Metastasis in Muscle-Invasive Bladder Cancer Following Neoadjuvant Therapy
Garrett K. Harada, Steven N. Seyedin, Olivia Heutlinger, Armon Azizi, Audree Hsu, Arash Rezazadeh, Michael Daneshvar, Greg E. Gin, Edward M. Uchio, Giovanna A. Giannico, Jeremy P. Harris, Aaron B. Simon, Jeffrey V. Kuo, Nataliya Mar
Advances in Radiation Oncology.2025; 10(1): 101671. CrossRef
Influence of Neoadjuvant Chemotherapy on Survival Outcomes of Radical Cystectomy in Pathologically Proven Positive and Negative Lymph Nodes
Krystian Kaczmarek, Bartosz Małkiewicz, Karolina Skonieczna-Żydecka, Artur Lemiński
Cancers.2023; 15(19): 4901. CrossRef
Comparison of responses to neoadjuvant and adjuvant chemotherapies in muscle-invasive bladder cancer
Serhat Sekmek, Gökhan Ucar, Irfan Karahan, Dogan Bayram, Selin Aktürk Esen, Ismet Seven, Mehmet Ali Nahit Sendur, Dogan Uncu
African Journal of Urology.2023;[Epub] CrossRef

5,304 View
181 Download
3 Web of Science
3 Crossref

Genitourinary Cancer

Use of Gemcitabine plus Carboplatin is Associated with Poor Outcomes in Urothelial Carcinoma Patients with Chronic Kidney Disease Stage 4-5: Hyung-Don Kim, Hyeon-Su Im, Jwa Hoon Kim, Hyehyun Jeong, Shin Kyo Yoon, Inkeun Park, Jae Lyun Lee; Cancer Res Treat. 2021;53(4):1166-1173. Published online March 4, 2021; DOI: https://doi.org/10.4143/crt.2021.091

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study aimed to investigate the clinical outcomes with gemcitabine-carboplatin (GCb), the standard treatment for patients with advanced urothelial carcinoma (UC) who are ineligible for cisplatin-based regimens, in advanced UC patients with a glomerular filtration rate (GFR) < 30 mL/min.
Materials and Methods
A retrospective cohort study involving GCb-treated advanced UC patients with GFR < 60 mL/min (n=89) was performed. Clinical outcomes were compared between subgroups with GFR < 30 mL/min and GFR ≥ 30 mL/min but < 60 mL/min.
Results
Most baseline characteristics were comparable between the two subgroups. Patients with GFR < 30 mL/min had a significantly lower objective response rate (12.5%) compared to those with higher GFR levels (56.7%) (p=0.004). The number of GCb cycles was significantly lower in patients with GFR < 30 mL/min (median 2 cycles) than in those with higher GFR levels (median 6 cycles) (p=0.002). Compared to those with GFR ≥ 30 mL/min but < 60 mL/min, patients with GFR < 30 mL/min showed significantly worse progression-free survival (PFS) and overall survival (OS) (p < 0.001 for both). Further stratification of patient subgroups according to their GFR (i.e., GFR ≥ 45 mL/min but < 60 mL/min vs. GFR ≥ 30 mL/min but < 45 mL/min vs. GFR < 30 mL/min) revealed significantly different PFS and OS (p < 0.001 for both).
Conclusion
The use of GCb is discouraged in advanced UC patients with GFR < 30 mL/min. Alternative therapeutic approaches with better efficacy are warranted for these patients.

Citations

Citations to this article as recorded by

Onconephrology: mitigation of renal injury in chemotherapy administration
Umut Selamet, Rebecca S. Ahdoot, Reed Salasnek, Lama Abdelnour, Ramy M. Hanna
Current Opinion in Nephrology & Hypertension.2024; 33(2): 257. CrossRef
Management of bladder cancer in older patients
Shingo Hatakeyama, Shintaro Narita, Kazutaka Okita, Takuma Narita, Hiromichi Iwamura, Naoki Fujita, Junichi Inokuchi, Yoshiyuki Matsui, Hiroshi Kitamura, Chikara Ohyama
Japanese Journal of Clinical Oncology.2022; 52(3): 203. CrossRef

5,157 View
117 Download
2 Web of Science
2 Crossref

Bevacizumab Plus Erlotinib Combination Therapy for Advanced Hereditary Leiomyomatosis and Renal Cell Carcinoma-Associated Renal Cell Carcinoma: A Multicenter Retrospective Analysis in Korean Patients: Yeonjoo Choi, Bhumsuk Keam, Miso Kim, Shinkyo Yoon, Dalyong Kim, Jong Gwon Choi, Ja Young Seo, Inkeun Park, Jae Lyun Lee; Cancer Res Treat. 2019;51(4):1549-1556. Published online March 25, 2019; DOI: https://doi.org/10.4143/crt.2019.086

Abstract PDF Supplementary Material PubReader ePub

Purpose
Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a rare genetic syndrome resulting from germline mutations in fumarate hydratase. The combination of bevacizumab plus erlotinib showed promising interim results for HLRCC-associated RCC. Based on these results, we analyzed the outcome of bevacizumab plus erlotinib in Korean patients with HLRCC-associated RCC.
Materials and Methods
We retrospectively reviewed the efficacy and safety of bevacizumab plus erlotinib in patients with HLRCC-associated RCC who were confirmed to have germline mutations in fumarate hydratase. The primary endpoint was the objective response rate (ORR), while the secondary endpoints were progression-free survival (PFS) and overall survival (OS).
Result
We identified 10 patients with advanced HLRCC-associated RCC who received bevacizumab plus erlotinib. Median age at diagnosis was 41 years, and five of the patients had received the combination as first- or second-line treatments. The ORR was 50% and the median PFS and OS were 13.3 and 14.1 months, respectively. Most adverse events were predictable and manageable by conventional measures, except for one instance where a patient died of gastrointestinal bleeding.
Conclusion
This is the first real-world outcome of the treatment of advanced HLRCC-associated RCC. Bevacizumab plus erlotinib therapy showed promising activity with moderate toxicity. We should be increasingly aware of HLRCC-associated RCC and bevacizumab plus erlotinib should be a first-line treatment for this condition, unless other promising data are published.

Citations

Citations to this article as recorded by

A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer
Ritesh R. Kotecha, Sahil D. Doshi, Andrea Knezevic, Joshua Chaim, Yingbei Chen, Rachel Jacobi, Mark Zucker, Ed Reznik, Deaglan McHugh, Neil J. Shah, Emily Feld, David H. Aggen, William Rafelson, Han Xiao, Maria I. Carlo, Darren R. Feldman, Chung-Han Lee,
European Urology Oncology.2024; 7(4): 804. CrossRef
Hereditary Renal Cancer Syndromes
Grigory A. Yanus, Ekaterina Sh. Kuligina, Evgeny N. Imyanitov
Medical Sciences.2024; 12(1): 12. CrossRef
Fumarate Hydratase-Deficient Renal Cell Carcinoma—A Clinicopathological Study of a Series of 11 Cases
Aswathy A. Menon, Swapnil Rane, Uma Sakhadeo, Gagan Prakash, Amit Joshi, Mahendra Pal, Amandeep Arora, Nilesh Sable, Aparna Katdare, Palak Popat, Priyamvada Maitre, Archi Agarwal, Vedang Murthy, Sangeetha B. Desai, Santosh Menon
Indian Journal of Medical and Paediatric Oncology.2024;[Epub] CrossRef
Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase–Deficient Renal Cell Carcinoma
Junru Chen, Xu Hu, Junjie Zhao, Xiaoxue Yin, Linmao Zheng, Jingjing Guo, Jianhui Chen, Yongquan Wang, Xinan Sheng, Haiying Dong, Xiaodong Liu, Xingming Zhang, Jiayu Liang, Haolin Liu, Jin Yao, Jiyan Liu, Yali Shen, Zhibin Chen, Zhengyu He, Yaodong Wang, N
Clinical Cancer Research.2024; 30(11): 2571. CrossRef
Comparison of Primary and Metastatic Fumarate Hydratase-Deficient Renal Cell Carcinomas Documents Morphologic Divergence and Potential Diagnostic Pitfall With Peritoneal Mesothelioma
Anna Caliò, Stefano Marletta, Lavinia Stefanizzi, Lisa Marcolini, Matteo Rotellini, Gabriella Serio, Elena Bariani, Caterina Vicentini, Serena Pedron, Filippo M. Martelli, Pietro Antonini, Matteo Brunelli, Guido Martignoni
Modern Pathology.2024; 37(9): 100561. CrossRef
Bevacizumab-Based Therapies in Malignant Tumors—Real-World Data on Effectiveness, Safety, and Cost
Elena Chitoran, Vlad Rotaru, Sinziana-Octavia Ionescu, Aisa Gelal, Cristina-Mirela Capsa, Roxana-Elena Bohiltea, Madalina-Nicoleta Mitroiu, Dragos Serban, Giuseppe Gullo, Daniela-Cristina Stefan, Laurentiu Simion
Cancers.2024; 16(14): 2590. CrossRef
Clinical Practice Recommendations for the Use of Next-Generation Sequencing in Patients with Solid Cancer: A Joint Report from KSMO and KSP
Miso Kim, Hyo Sup Shim, Sheehyun Kim, In Hee Lee, Jihun Kim, Shinkyo Yoon, Hyung-Don Kim, Inkeun Park, Jae Ho Jeong, Changhoon Yoo, Jaekyung Cheon, In-Ho Kim, Jieun Lee, Sook Hee Hong, Sehhoon Park, Hyun Ae Jung, Jin Won Kim, Han Jo Kim, Yongjun Cha, Sun
Cancer Research and Treatment.2024; 56(3): 721. CrossRef
Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer: a joint report from KSMO and KSP
Miso Kim, Hyo Sup Shim, Sheehyun Kim, In Hee Lee, Jihun Kim, Shinkyo Yoon, Hyung-Don Kim, Inkeun Park, Jae Ho Jeong, Changhoon Yoo, Jaekyung Cheon, In-Ho Kim, Jieun Lee, Sook Hee Hong, Sehhoon Park, Hyun Ae Jung, Jin Won Kim, Han Jo Kim, Yongjun Cha, Sun
Journal of Pathology and Translational Medicine.2024; 58(4): 147. CrossRef
Complete response to fifth-line anti-PD-1 rechallenge in fumarate hydratase-mutated papillary renal cell carcinoma
Isabella Portugal, Maria A. Clavijo-Salomon
npj Precision Oncology.2024;[Epub] CrossRef
Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma
Yunze Xu, Wen Kong, Ming Cao, Jieying Wang, Zaoyu Wang, Liang Zheng, Xiaoyu Wu, Rongrong Cheng, Wei He, Bo Yang, Baijun Dong, Jiahua Pan, Yonghui Chen, Jiwei Huang, Chen Jiang, Wei Zhai, Fangzhou Li, Ruohua Chen, Xiang Zhou, Guangyu Wu, Xiaochuan Geng, Ji
European Urology.2023; 83(2): 163. CrossRef
Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the Literature
Alexius John, Lavinia Spain, Anis A. Hamid
Current Oncology.2023; 30(1): 923. CrossRef
CLC-Pred 2.0: A Freely Available Web Application for In Silico Prediction of Human Cell Line Cytotoxicity and Molecular Mechanisms of Action for Druglike Compounds
Alexey A. Lagunin, Anastasia V. Rudik, Pavel V. Pogodin, Polina I. Savosina, Olga A. Tarasova, Alexander V. Dmitriev, Sergey M. Ivanov, Nadezhda Y. Biziukova, Dmitry S. Druzhilovskiy, Dmitry A. Filimonov, Vladimir V. Poroikov
International Journal of Molecular Sciences.2023; 24(2): 1689. CrossRef
Fumarate Hydratase-deficient Renal Cell Carcinoma
Yi-Hsuan Huang, Nan-Haw Chow, Yu-Ting Yu, Wen-Pin Su
Journal of Cancer Research and Practice.2023; 10(1): 28. CrossRef
Diseases of Hereditary Renal Cell Cancers
Othon Iliopoulos
Urologic Clinics of North America.2023; 50(2): 205. CrossRef
Hereditary Leiomyomatosis and Renal Cell Cancer: A Case Report of Pilar Leiomyomatosis with History of Kidney Cancer and Review of the Literature
Jee-Woo Kim, Jung-Won Shin, Anna Cho, Chang-Hun Huh
Annals of Dermatology.2023;[Epub] CrossRef
Clinical Characteristics of Molecularly Defined Renal Cell Carcinomas
Xinfeng Hu, Congzhu Tan, Guodong Zhu
Current Issues in Molecular Biology.2023; 45(6): 4763. CrossRef
Hereditary predisposition to kidney cancer: cancer syndromes, multisystemic disorders, and nephropathies
G. A. Yanus, A. G. Iyevleva, E. N. Suspitsin, A. V. Tumakova, E. V. Belogubova, S. N. Aleksakhina, A. V. Togo, E. N. Imyanitov
Sechenov Medical Journal.2023; 14(2): 5. CrossRef
Hereditary leiomyomatosis and renal cell cancer associated with metastatic rectal cancer
Parikshit Padhi, Naga Praneeth Raja
Current Problems in Cancer: Case Reports.2023; 11: 100257. CrossRef
Unmasking the enigma: A case of Fumarate Hydratase-deficient renal cell carcinoma
Mirza Rameez Samar, Wajiha Khan, Yasmin Abdul Rashid, Azmina Tajuddin Vali Mohammad
International Journal of Surgery Case Reports.2023; 113: 109054. CrossRef
Tumors masquerading as type 2 papillary renal cell carcinoma: pathologists’ ever-expanding differential diagnosis for a heterogeneous group of entities
Alexander S. Taylor, Stephanie L. Skala
Urologic Oncology: Seminars and Original Investigations.2022; 40(12): 499. CrossRef
Low-Grade Fumarate Hydratase-Deficient Renal Cell Carcinoma in a 30-Year-Old Female
Nicolas Wyvekens, William J. Anderson, Young X. Kim, Mark Carter, Michelle S. Hirsch
International Journal of Surgical Pathology.2022; 30(2): 184. CrossRef
Response to the Letter to the Editor Entitled “Do We Have Sufficient Evidence to Define Prognosis for ‘Low-grade’ Fumarate Hydratase-deficient Renal Cell Carcinoma?”
Steven C. Smith, Ameer Hamza, Deepika Sirohi, Mahul B. Amin
Advances in Anatomic Pathology.2022; 29(3): 181. CrossRef
Hereditary Renal Cell Carcinoma
Scott J. Dawsey, Shilpa Gupta
Kidney Cancer.2022; 6(2): 83. CrossRef
A Phase II, Single-arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell Carcinoma
Zizhen Feng, Brendan D. Curti, David I. Quinn, John M. Strother, Zunqiu Chen, Rebecca Agnor, Tomasz M. Beer, Christopher W. Ryan
Clinical Genitourinary Cancer.2022; 20(5): 415. CrossRef
Targeting strategies in the treatment of fumarate hydratase deficient renal cell carcinoma
Andrea Katharina Lindner, Gennadi Tulchiner, Andreas Seeber, Peter J. Siska, Martin Thurnher, Renate Pichler
Frontiers in Oncology.2022;[Epub] CrossRef
MR Spectroscopy for Detecting Fumarate Hydratase Deficiency in Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome
Guangyu Wu, Guiqin Liu, Jianfeng Wang, Shihang Pan, Yuansheng Luo, Yunze Xu, Wen Kong, Peng Sun, Jianrong Xu, Wei Xue, Jin Zhang
Radiology.2022; 305(3): 631. CrossRef
Complete response of hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated renal cell carcinoma to nivolumab and ipilimumab combination immunotherapy by: a case report
Yasuhiro Iribe, Mitsuko Furuya, Yousuke Shibata, Masato Yasui, Makoto Funahashi, Junichi Ota, Hiromichi Iwashita, Yoji Nagashima, Hisashi Hasumi, Narihiko Hayashi, Kazuhide Makiyama, Keiichi Kondo, Reiko Tanaka, Masahiro Yao, Noboru Nakaigawa
Familial Cancer.2021; 20(1): 75. CrossRef
Genotypic and Phenotypic Characteristics of Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome in Korean Patients
Ja Young Seo, Jeong-Yeal Ahn, Bhumsuk Keam, Miso Kim, Shinkyo Yoon, Jae Lyun Lee, Kwonoh Park, Inkeun Park
Annals of Laboratory Medicine.2021; 41(2): 207. CrossRef
Integrated Molecular Characterization of Fumarate Hydratase–deficient Renal Cell Carcinoma
Guangxi Sun, Xingming Zhang, Jiayu Liang, Xiuyi Pan, Sha Zhu, Zhenhua Liu, Cameron M. Armstrong, Jianhui Chen, Wei Lin, Banghua Liao, Tianhai Lin, Rui Huang, Mengni Zhang, Linmao Zheng, Xiaoxue Yin, Ling Nie, Pengfei Shen, Jinge Zhao, Haoran Zhang, Jindon
Clinical Cancer Research.2021; 27(6): 1734. CrossRef
Durable Major Response With Pazopanib in Recurrent, Heavily Pretreated Metastatic Esthesioneuroblastoma Harboring a Fumarate Hydratase Mutation
Marianne Spengler, Megan Wheelden, Heath B. Mackley, Joseph J. Drabick
JCO Precision Oncology.2021; (5): 664. CrossRef
Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma
Andrew J. Wiele, Devaki Shilpa Surasi, Priya Rao, Kanishka Sircar, Xiaoping Su, Tharakeswara K. Bathala, Amishi Y. Shah, Eric Jonasch, Vince D. Cataldo, Giannicola Genovese, Jose A. Karam, Christopher G. Wood, Nizar M. Tannir, Pavlos Msaouel
Cancers.2021; 13(9): 2170. CrossRef
Response to systemic therapy in fumarate hydratase–deficient renal cell carcinoma
Lucia Carril-Ajuria, Emeline Colomba, Luigi Cerbone, Carmen Romero-Ferreiro, Laurence Crouzet, Brigitte Laguerre, Constance Thibault, Cécile Vicier, Guillermo de Velasco, Aude Fléchon, Carolina Saldana, Patrick R. Benusiglio, Brigitte Bressac-de Pailleret
European Journal of Cancer.2021; 151: 106. CrossRef
Hereditary Leiomyomatosis and Renal Cell Cancer: Recent Insights Into Mechanisms and Systemic Treatment
Congwang Zhang, Lijun Li, Yipeng Zhang, Changchun Zeng
Frontiers in Oncology.2021;[Epub] CrossRef
Hereditary leiomyomatosis and renal cell cancer presenting as urothelial carcinoma
Samuel B Reynolds, Rishi Charate, Quang L Nguyen, Padmini Moffett
Journal of Onco-Nephrology.2021; 5(3): 178. CrossRef
Das FH-defiziente Nierenzellkarzinom erweitert das Spektrum der papillären Tumoren in der Niere
N. Rupp, H. Moch
Der Pathologe.2021; 42(6): 560. CrossRef
To treat or not to treat: a clinical series of retinal arterial macroaneurysms
Wan-Hua Cho, Wei-Yu Chiang, Chih-Hsin Chen, Hsi-Kung Kuo
Medicine.2020; 99(5): e19077. CrossRef
Bevacizumab/erlotinib

Reactions Weekly.2020; 1798(1): 61. CrossRef
On the Shoulders of Giants: The Evolution of Renal Cell Carcinoma Treatment—Cytokines, Targeted Therapy, and Immunotherapy
Janice P. Dutcher, Ronan Flippot, Jaleh Fallah, Bernard Escudier
American Society of Clinical Oncology Educational Book.2020; (40): 418. CrossRef
Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in HLRCC syndrome patients with a tailored therapeutic approach
Nicolas Wyvekens, Nadejda Valtcheva, Axel Mischo, Birgit Helmchen, Thomas Hermanns, Matthias Choschzick, Andreas M. Hötker, Anita Rauch, Beda Mühleisen, Dilara Akhoundova, Achim Weber, Holger Moch, Niels J. Rupp
Genes, Chromosomes and Cancer.2020; 59(11): 611. CrossRef
Fumarate hydratase as a therapeutic target in renal cancer
Priyanka Kancherla, Michael Daneshvar, Rebecca A. Sager, Mehdi Mollapour, Gennady Bratslavsky
Expert Opinion on Therapeutic Targets.2020; 24(9): 923. CrossRef
Construct a circRNA/miRNA/mRNA regulatory network to explore potential pathogenesis and therapy options of clear cell renal cell carcinoma
Shuheng Bai, YinYing Wu, Yanli Yan, Shuai Shao, Jiangzhou Zhang, Jiaxin Liu, Beina Hui, Rui Liu, Hailin Ma, Xiaozhi Zhang, Juan Ren
Scientific Reports.2020;[Epub] CrossRef

8,352 View
324 Download
40 Web of Science
41 Crossref

Phase II Study of Dovitinib in Patients with Castration-Resistant Prostate Cancer (KCSG-GU11-05): Yoon Ji Choi, Hye Sook Kim, Se Hoon Park, Bong-Seog Kim, Kyoung Ha Kim, Hyo Jin Lee, Hong Suk Song, Dong-Yeop Shin, Ha Young Lee, Hoon-Gu Kim, Kyung Hee Lee, Jae Lyun Lee, Kyong Hwa Park; Cancer Res Treat. 2018;50(4):1252-1259. Published online January 2, 2018; DOI: https://doi.org/10.4143/crt.2017.438

Abstract PDF PubReader ePub

Purpose
Fibroblast growth factor (FGF) signals are important in carcinogenesis and progression of prostate cancer. Dovitinib is an oral, pan-class inhibitor of vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor, and fibroblast growth factor receptor (FGFR). We evaluated the efficacy and toxicity of dovitinib in men with metastatic castration resistant prostate cancer (mCRPC).
Materials and Methods
This study was a single-arm, phase II, open-label, multicenter trial of dovitinib 500 mg/day (5-days-on/2-days-off schedule). The primary endpointwas 16-week progression-free survival (PFS). Secondary endpoints were overall survival (OS), toxicity and prostate-specific antigen (PSA) response rate. Biomarker analyses for VEGFR2, FGF23, and FGFR2 using multiplex enzyme-linked immunosorbent assay was performed.
Results
Forty-four men were accrued from 11 hospitals. Eighty percent were post-docetaxel. Median PSA was 100 ng/dL, median age was 69, 82% had bone metastases, and 23% had liver metastases. Median cycles of dovitinibwas 2 (range, 0 to 33). Median PFSwas 3.67 months (95% confidence interval [CI], 1.36 to 5.98) and median OS was 13.70 months (95% CI, 0 to 27.41). Chemotherapy-naïve patients had longer PFS (17.90 months; 95% CI, 9.23 to 28.57) compared with docetaxel-treated patients (2.07 months; 95% CI, 1.73 to 2.41; p=0.001) and the patients with high serum VEGFR2 level over median level (7,800 pg/mL) showed longer PFS compared with others (6.03 months [95% CI, 4.26 to 7.80] vs. 1.97 months [95% CI, 1.79 to 2.15], p=0.023). Grade 3 related adverse events were seen in 40.9% of patients. Grade 1-2 nausea, diarrhea, fatigue, anorexia, and all grade thrombocytopenia are common.
Conclusion
Dovitinib showed modest antitumor activity with manageable toxicities in men with mCRPC. Especially, patients who were chemo-naïve benefitted from dovitinib.

Citations

Citations to this article as recorded by

Comprehensive Review on Recent Strategies for Management of Prostate Cancer: Therapeutic Targets and SAR
Manish Chaudhary, Shubham Kumar, Paranjeet Kaur, Sanjeev Kumar Sahu, Amit Mittal
Mini-Reviews in Medicinal Chemistry.2024; 24(7): 721. CrossRef
Role of Basic Fibroblast Growth Factor in Cancer: Biological Activity, Targeted Therapies, and Prognostic Value
Alessio Ardizzone, Valentina Bova, Giovanna Casili, Alberto Repici, Marika Lanza, Raffaella Giuffrida, Cristina Colarossi, Marzia Mare, Salvatore Cuzzocrea, Emanuela Esposito, Irene Paterniti
Cells.2023; 12(7): 1002. CrossRef
Case Report of a Glioma Patient with Homozygous Missense Amino Acid Substitution in KDR Gene
Kalyan Ram Uppaluri, Himavanth Reddy Kambalachenu, Hima Jyothi Challa, Saadvik Raghuram Y., Deepak Sharma, Ramya Gadicherla, Srinivas Ketavath, Kalyani Palasamudram, Sri Manjari K.
Indian Journal of Medical and Paediatric Oncology.2023; 44(03): 356. CrossRef
FGFR families: biological functions and therapeutic interventions in tumors
Qing Liu, Jiyu Huang, Weiwei Yan, Zhen Liu, Shu Liu, Weiyi Fang
MedComm.2023;[Epub] CrossRef
Targeting transforming growth factor‐ß signalling for cancer prevention and intervention: Recent advances in developing small molecules of natural origin
Devesh Tewari, Anu Priya, Anusha Bishayee, Anupam Bishayee
Clinical and Translational Medicine.2022;[Epub] CrossRef
Evaluation of the therapeutic potential of masitinib and expression of its specific targets c‐Kit, PDGFR‐α, PDGFR‐β, and Lyn in canine prostate cancer cell lines
Katharina Klose, Eva‐Maria Packeiser, José‐Luis Granados‐Soler, Marion Hewicker‐Trautwein, Hugo Murua Escobar, Ingo Nolte
Veterinary and Comparative Oncology.2022; 20(3): 641. CrossRef
Phase 2 Study of Neoadjuvant FGFR Inhibition and Androgen Deprivation Therapy Prior to Prostatectomy
Elizabeth Liow, Nicholas Howard, Chol-Hee Jung, Bernard Pope, Bethany K. Campbell, Anne Nguyen, Michael Kerger, Jonathan B. Ruddle, Angelyn Anton, Benjamin Thomas, Kevin Chu, Philip Dundee, Justin S. Peters, Anthony J. Costello, Andrew S. Ryan, Christophe
Clinical Genitourinary Cancer.2022; 20(5): 452. CrossRef
There are gremlins in prostate cancer
Laura A. Sena, W. Nathaniel Brennen, John T. Isaacs
Nature Cancer.2022; 3(5): 530. CrossRef
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
Yundong He, Weidong Xu, Yu-Tian Xiao, Haojie Huang, Di Gu, Shancheng Ren
Signal Transduction and Targeted Therapy.2022;[Epub] CrossRef
Concept of Hybrid Drugs and Recent Advancements in Anticancer Hybrids
Ankit Kumar Singh, Adarsh Kumar, Harshwardhan Singh, Pankaj Sonawane, Harshali Paliwal, Suresh Thareja, Prateek Pathak, Maria Grishina, Mariusz Jaremko, Abdul-Hamid Emwas, Jagat Pal Yadav, Amita Verma, Habibullah Khalilullah, Pradeep Kumar
Pharmaceuticals.2022; 15(9): 1071. CrossRef
The FGF/FGFR system in the physiopathology of the prostate gland
Arianna Giacomini, Elisabetta Grillo, Sara Rezzola, Domenico Ribatti, Marco Rusnati, Roberto Ronca, Marco Presta
Physiological Reviews.2021; 101(2): 569. CrossRef
Signaling Pathways That Control Apoptosis in Prostate Cancer
Amaal Ali, George Kulik
Cancers.2021; 13(5): 937. CrossRef
A Review of the Pathophysiological Mechanisms Underlying Castration-resistant Prostate Cancer
Fionnuala Crowley, Michelle Sterpi, Conor Buckley, Lauren Margetich, Shivani Handa, Zach Dovey
Research and Reports in Urology.2021; Volume 13: 457. CrossRef
Neoadjuvant Treatment with Angiogenesis-Inhibitor Dovitinib Prior to Local Therapy in Hepatocellular Carcinoma: A Phase II Study
F.J. Sherida H. Woei-A-Jin, Nir I. Weijl, Mark C. Burgmans, Arantza Fariña Sarasqueta, J. Tom van Wezel, Martin N.J.M. Wasser, Minneke J. Coenraad, Jacobus Burggraaf, Susanne Osanto
The Oncologist.2021; 26(10): 854. CrossRef
Reprogramming of Protein-Targeted Small-Molecule Medicines to RNA by Ribonuclease Recruitment
Peiyuan Zhang, Xiaohui Liu, Daniel Abegg, Toru Tanaka, Yuquan Tong, Raphael I. Benhamou, Jared Baisden, Gogce Crynen, Samantha M. Meyer, Michael D. Cameron, Arnab K. Chatterjee, Alexander Adibekian, Jessica L. Childs-Disney, Matthew D. Disney
Journal of the American Chemical Society.2021; 143(33): 13044. CrossRef
Bone microenvironment signaling of cancer stem cells as a therapeutic target in metastatic prostate cancer
Clara H. Lee, Ann M. Decker, Frank C. Cackowski, Russell S. Taichman
Cell Biology and Toxicology.2020; 36(2): 115. CrossRef
Brivanib, a multitargeted small‐molecule tyrosine kinase inhibitor, suppresses laser‐induced CNV in a mouse model of neovascular AMD
Lele Li, Manhui Zhu, Wenli Wu, Bai Qin, Jiayi Gu, Yuanyuan Tu, Jianing Chen, Dong Liu, Yunwei Shi, Xiaojuan Liu, Aimin Sang, Dongmei Ding
Journal of Cellular Physiology.2020; 235(2): 1259. CrossRef
In Vitro Effect of Dovitinib (TKI258), a Multi-Target Angiokinase Inhibitor on Aggressive Meningioma Cells
Arabinda Das, Jaime L. Martinez Santos, Mohammed Alshareef, Guilherme Bastos Ferreira Porto, Libby Kosnik Infinger, William A. Vandergrift, Scott M. Lindhorst, Abhay K. Varma, Sunil J. Patel, David Cachia
Cancer Investigation.2020; 38(6): 349. CrossRef
Potential Role of Targeting KDR and Proteasome Inhibitors in the Therapy of Esophageal Squamous Cell Carcinoma
Ling Zhang, Xia Niu, Yanghui Bi, Heyang Cui, Hongyi Li, Xiaolong Cheng
Technology in Cancer Research & Treatment.2020;[Epub] CrossRef
Novel Therapeutic Strategies for CDK4/6 Inhibitors in Metastatic Castrate-Resistant Prostate Cancer

Adam M. Kase, John A. Copland, Winston Tan
OncoTargets and Therapy.2020; Volume 13: 10499. CrossRef
Therapeutic implications of fibroblast growth factor receptor inhibitors in a combination regimen for solid tumors (Review)
Hong Luo, Tao Zhang, Peng Cheng, Dong Li, Oleksandr Ogorodniitchouk, Chaimaa Lahmamssi, Ge Wang, Meiling Lan
Oncology Letters.2020; 20(3): 2525. CrossRef
Dovitinib Triggers Apoptosis and Autophagic Cell Death by Targeting SHP-1/p-STAT3 Signaling in Human Breast Cancers
Yi-Han Chiu, Yi-Yen Lee, Kuo-Chin Huang, Cheng-Chi Liu, Chen-Si Lin
Journal of Oncology.2019; 2019: 1. CrossRef
Tumour-stroma ratio and 5-year mortality in gastric adenocarcinoma: a systematic review and meta-analysis
Niko Kemi, Maarit Eskuri, Joonas H. Kauppila
Scientific Reports.2019;[Epub] CrossRef
Investigational fibroblast growth factor receptor 2 antagonists in early phase clinical trials to treat solid tumors
Dan Wang, Li Yang, Weina Yu, Yi Zhang
Expert Opinion on Investigational Drugs.2019; 28(10): 903. CrossRef
A Novel FGFR3 Splice Variant Preferentially Expressed in African American Prostate Cancer Drives Aggressive Phenotypes and Docetaxel Resistance
Jacqueline Olender, Bi-Dar Wang, Travers Ching, Lana X. Garmire, Kaitlin Garofano, Youngmi Ji, Tessa Knox, Patricia Latham, Kenneth Nguyen, Johng Rhim, Norman H. Lee
Molecular Cancer Research.2019; 17(10): 2115. CrossRef
Recent Advances in Prostate Cancer Treatment and Drug Discovery
Ekaterina Nevedomskaya, Simon J. Baumgart, Bernard Haendler
International Journal of Molecular Sciences.2018; 19(5): 1359. CrossRef

10,957 View
246 Download
28 Web of Science
26 Crossref

Case Reports

Conventional Cisplatin-Based Combination Chemotherapy Is Effective in the Treatment of Metastatic Spermatocytic Seminoma with Extensive Rhabdomyosarcomatous Transformation: Yumun Jeong, Jaekyung Cheon, Tae-Oh Kim, Doo-Ho Lim, Sunpyo Lee, Young-Mi Cho, Jun Hyuk Hong, Jae Lyun Lee; Cancer Res Treat. 2015;47(4):931-936. Published online September 11, 2014; DOI: https://doi.org/10.4143/crt.2014.049

Abstract PDF PubReader ePub

A 52-year-old man was presented with a huge left testicular mass and palpable cervical lymphadenopathy with retroperitoneal lymph node enlargement on an abdominal computed tomography. A left radical orchiectomy and an ultrasound-guided neck node biopsy were performed. A pathological examination revealed spermatocytic seminoma with extensive rhabdomyosarcomatous transformation, a condition known to be highly resistant to platinum-based chemotherapy. The patient received four cycles of etoposide, ifosfamide and cisplatin (VIP) chemotherapy. A repeat computed tomography revealed a substantial regression consistent with a partial response. Retroperitoneal lymph node dissection was attempted, which revealed rhabdomyosarcoma; however, complete microscopic resection was not achieved. After surgery, the residual abdominal lymph node progressed and salvage paclitaxel, ifosfamide and cisplatin (TIP) chemotherapy was employed, which again achieved a partial response. Here, we present a first case report of a spermatocytic seminoma with extensive rhabdomyosarcomatous transformation and multiple metastatic lymphadenopathies that showed a favorable response to platinum-based systemic chemotherapy.

Citations

Citations to this article as recorded by

Case of the month from the Department of Medical Oncology, Peter MacCallum Cancer Centre, University of Melbourne, Australia: recurrent metastatic spermatocytic tumour successfully treated with salvage systemic chemotherapy
Jane McKenzie, Catherine Mitchell, Jeremy Lewin, Ciara Conduit
BJU International.2024; 134(6): 922. CrossRef
Sarcomatoid Spermatocytic Tumour: Report of a Rare Case and Literature Review
André Fontes Dias, Eugénia Dvindenko, Filipa Santos, Rafael Cabrera
International Journal of Surgical Pathology.2023; 31(5): 728. CrossRef
Spermatocytic Tumor: A Review
Simona Secondino, Alessandra Viglio, Giuseppe Neri, Giulia Galli, Carlotta Faverio, Federica Mascaro, Richard Naspro, Giovanni Rosti, Paolo Pedrazzoli
International Journal of Molecular Sciences.2023; 24(11): 9529. CrossRef
Spermatocytic seminoma of testis associated with undifferentiated sarcoma revealed in metastatic disease: A review and case report analysis
Mehdi Chennoufi, Ibrahim Boukhannous, Mohamed Mokhtari, Anouar El Moudane, Ali Barki
Urology Case Reports.2021; 38: 101732. CrossRef

26,993 View
88 Download
5 Web of Science
4 Crossref

Sunitinib Treatment for Metastatic Renal Cell Carcinoma in Patients with Von Hippel-Lindau Disease: Ho Cheol Kim, Jung Su Lee, Sang Hyung Kim, Hoon Sub So, Chang Yoon Woo, Jae Lyun Lee; Cancer Res Treat. 2013;45(4):349-353. Published online December 31, 2013; DOI: https://doi.org/10.4143/crt.2013.45.4.349

Abstract PDF PubReader ePub

Von Hippel-Lindau (VHL) disease is an autosomal dominant disease that produces a variety of tumors and cysts in the central nervous system and visceral organs, including renal cell carcinoma (RCC). RCC in patients with VHL disease does not frequently metastasize, therefore, the response to treatment and prognosis of metastatic RCC developed in patients with VHL disease has not been reported. Sunitinib is an oral, multitargeted receptor tyrosine kinase inhibitor with antiangiogenic and antitumor activity. Here, we report on four patients with metastatic RCC in VHL disease who received sunitinib and achieved partial responses that have lasted for a prolonged period of time.

Citations

Citations to this article as recorded by

The Clinical and Molecular Features in the VHL Renal Cancers; Close or Distant Relatives with Sporadic Clear Cell Renal Cell Carcinoma?
Alessandra Cinque, Roberto Minnei, Matteo Floris, Francesco Trevisani
Cancers.2022; 14(21): 5352. CrossRef
Hereditary renal cell tumors: Clinicopathologic importance
Harmanjot Singh, Mukul K. Divatia, Donghwa Baek, Jae Y. Ro
annals of urologic oncology.2021;[Epub] CrossRef
Von Hippel-Lindau Disease: Current Challenges and Future Prospects

Sven Gläsker, Evelynn Vergauwen, Christian A Koch, Alexander Kutikov, Alexander O Vortmeyer
OncoTargets and Therapy.2020; Volume 13: 5669. CrossRef
The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma
Song Peng, Jun Zhang, Xintao Tan, Yiqiang Huang, Jing Xu, Natalie Silk, Dianzheng Zhang, Qiuli Liu, Jun Jiang
Frontiers in Endocrinology.2020;[Epub] CrossRef
Familial Kidney Cancer: Implications of New Syndromes and Molecular Insights
Maria I. Carlo, A. Ari Hakimi, Grant D. Stewart, Gennady Bratslavsky, James Brugarolas, Ying-Bei Chen, W. Marston Linehan, Eamonn R. Maher, Maria J. Merino, Kenneth Offit, Victor E. Reuter, Brian Shuch, Jonathan A. Coleman
European Urology.2019; 76(6): 754. CrossRef
The Efficacy and Safety of Tyrosine Kinase Inhibitors for Von Hippel–Lindau Disease: A Retrospective Study of 32 Patients
Kaifang Ma, Baoan Hong, Jingcheng Zhou, Yanqing Gong, Jiangyi Wang, Shengjie Liu, Xiang Peng, Bowen Zhou, Jiufeng Zhang, Haibiao Xie, Kenan Zhang, Lei Li, Desheng Cai, Zixin Wang, Lin Cai, Kan Gong
Frontiers in Oncology.2019;[Epub] CrossRef
A retrospective case study of sunitinib treatment in three patients with Von Hippel-Lindau disease
Gang Yuan, Qiuli Liu, Dali Tong, Gaolei Liu, Yuting Yi, Jun Zhang, Yao Zhang, Lin-ang Wang, Luofu Wang, Rongrong Chen, Yanfang Guan, Xin Yi, Weihua Lan, Jun Jiang
Cancer Biology & Therapy.2018; 19(9): 766. CrossRef
Genetic Predisposition to Renal Cell Carcinoma: Implications for Counseling, Testing, Screening, and Management
Brian Shuch, Jin Zhang
Journal of Clinical Oncology.2018; 36(36): 3560. CrossRef
A Case of von Hippel–Lindau Disease with Colorectal Adenocarcinoma, Renal Cell Carcinoma and Hemangioblastomas
Su Jin Heo, Choong-kun Lee, Kyu Yeon Hahn, Gyuri Kim, Hyuk Hur, Sung Hoon Choi, Kyung Seok Han, Arthur Cho, Minkyu Jung
Cancer Research and Treatment.2016; 48(1): 409. CrossRef
Attainment of a Long-term Favorable Outcome by Sunitinib Treatment for Pancreatic Neuroendocrine Tumor and Renal Cell Carcinoma Associated with von Hippel-Lindau Disease
Akihiro Kobayashi, Masanobu Takahashi, Hiroo Imai, Shoko Akiyama, Shunsuke Sugiyama, Keigo Komine, Ken Saijo, Masahiro Takahashi, Shin Takahashi, Hidekazu Shirota, Naomi Sato, Fumiyoshi Fujishima, Taro Shuin, Hideki Shimodaira, Chikashi Ishioka
Internal Medicine.2016; 55(6): 629. CrossRef
Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR group
Stéphane Oudard, Reza Elaidi, Mara Brizard, Céline Le Rest, Valérie Caillet, Sophie Deveaux, Gérard Benoit, Jean-Michel Corréas, Farida Benoudiba, Philippe David, Alain Gaudric, Pascal Hammel, Dominique Joly, Marc Olivier Timsit, Arnaud Méjean, Stéphane R
Oncotarget.2016; 7(51): 85306. CrossRef
Pharmacogenomic biomarkers for personalized cancer treatment
C. Rodríguez‐Antona, M. Taron
Journal of Internal Medicine.2015; 277(2): 201. CrossRef
Pharmacological HIF2α inhibition improves VHL disease–associated phenotypes in zebrafish model
Ana Martins Metelo, Haley R. Noonan, Xiang Li, Youngnam Jin, Rania Baker, Lee Kamentsky, Yiyun Zhang, Ellen van Rooijen, Jordan Shin, Anne E. Carpenter, Jing-Ruey Yeh, Randall T. Peterson, Othon Iliopoulos
Journal of Clinical Investigation.2015; 125(5): 1987. CrossRef
Molecular and immunologic markers of kidney cancer—potential applications in predictive, preventive and personalized medicine
Amanda Mickley, Olga Kovaleva, Julia Kzhyshkowska, Alexei Gratchev
EPMA Journal.2015;[Epub] CrossRef

11,959 View
70 Download
15 Web of Science
14 Crossref

Original Articles

Effect of Combination Chemotherapy with Docetaxel Plus Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer: Hee Jung Kang, Min Kyoung Kim, Young Gil Kim, Jae Lyun Lee, Kyung Hee Lee, Myung Soo Hyun, Sung Hwa Bae, Hun Mo Ryoo; Cancer Res Treat. 2003;35(4):299-303. Published online August 31, 2003; DOI: https://doi.org/10.4143/crt.2003.35.4.299

Abstract PDF: PURPOSE
This study was conducted to evaluate the efficacy and safety of combination chemotherapy, with docetaxel and cisplatin, as a first line treatment for advanced non-small cell lung cancer.
MATERIALS AND METHODS
Between March 1998 and December 2001, 35 patients with advanced non-small cell lung cancer were enrolled in this study. The patients were treated at 3-week intervals, with one course of a regimen consisting of docetaxel (75 mg/m2 IV for 1 hours) on day 1 and cisplatin (60 mg/m2 IV) on day 2.
RESULTS
The median age of the patients was 60.3 years. Of the 35 patients, 20 and 15 had stage IIIb and stage IV diseases, respectively. A complete response was observed in 1 patient and partial response in 15, with an overall response rate of 46%. The overall median survival duration was 40.3+/-25.2 weeks. The median time to progression and response duration were 21.6+/-5.5 and 15.1+/-5.9 weeks, respectively. The survival duration was statistically significantly longer in the response group (50.6 weeks) than in the non-response group (31.6 weeks) (p<0.05). Of the hematological side effects, grades III and IV leukopenia were observed in 4.8% of patients. Grades III and IV nausea and vomiting were observed in 48.5%, and grades I and II neuropathy in 11.4% of the treated patients. These toxicities were well tolerable and reversible. There were no hypersensitivity reactions.
CONCLUSION
Docetaxel and cisplatin combination chemotherapy is relatively effective and safe in advanced non-small cell lung cancer patients.

4,136 View
34 Download

Overexpression of c-met Protein in Gastric Cancer and Role of uPAR as a Therapeutic Target: Hyun A Oh, Gu Lee, Hee Jung Kang, Yong Gil Kim, Sung Hwa Bae, Jae Lyun Lee, Kyung Hee Lee, Myung Soo Hyun, Dong Suk Kim; Cancer Res Treat. 2003;35(1):9-15. Published online February 28, 2003; DOI: https://doi.org/10.4143/crt.2003.35.1.9

Abstract PDF

PURPOSE
One of the members of the tyrosine kinase receptor family is the protein product of the c-met proto-oncogene, which is the receptor for hepatocyte growth factor (HGF). HGF is known as a potent mitogen and motogen for many kinds of carcinoma cells, and has been found to simulate the growth and progression of gastric cancer cells through HGF-receptors. In addition, the urokinase-type plasminogen activator (uPA) and receptor (uPAR) also play important roles in the invasion and metastasis. MATERIALS AND METHODS: The expression of c-met protein was investigated using immunohistochemical staining of 50 paraffin embedded gastric cancers, and by measuring the serum uPAR levels, before and after an operation, in gastric cancer patients using an ELISA assay. RESULTS: Of the 50 cases, 32 (64%) expressed the c-met protein. The c-met protein expression was significantly correlated with the TNM staging (p<0.05), but the other prognostic factors were not significant variables. According to a Kaplan-Meier's plot, the one and three year overall survival rates were 94 and 70% in patients not expressing the c-met protein, and 81 and 33% in those that did, and the Survival curves revealed a significantly different prognosis (p=0.04). Elevated serum uPAR levels (> or=3257.8 pg/ml, control+/-mean 2SD) were observed in 9 (34.6%) of 26 gastric cancer patients, but in none of control subjects. Average serum uPAR levels were 2980.8+/-616.2 pg/ml before the operation and 2404.7+/-455.9 pg/ml after, and decreased significantly after surgical resection (p<0.05). The serum uPAR level correlated significantly with lymph node metastasis and vessel invasion (p<0.05) CONCLUSION: The expression of c-met protein, and the level of uPAR, may be prognostic factors in gastric cancer.

Citations

Citations to this article as recorded by

Ferroptosis regulating lipid peroxidation metabolism in the occurrence and development of gastric cancer
Lan-Mei Wang, Wei-Wei Zhang, Ying-Yang Qiu, Fang Wang
World Journal of Gastrointestinal Oncology.2024; 16(6): 2781. CrossRef
Research progress on the development of hepatocyte growth factor/c-Met signaling pathway in gastric cancer: A review
Wu-Jie Wei, Ya-Li Hong, Yi Deng, Guan-Liang Wang, Jiang-Tao Qiu, Fang Pan
World Journal of Gastrointestinal Oncology.2024; 16(8): 3397. CrossRef
Human Triosephosphate Isomerase Is a Potential Target in Cancer Due to Commonly Occurring Post-Translational Modifications
Sergio Enríquez-Flores, Ignacio De la Mora-De la Mora, Itzhel García-Torres, Luis A. Flores-López, Yoalli Martínez-Pérez, Gabriel López-Velázquez
Molecules.2023; 28(16): 6163. CrossRef
SMYD3 Modulates the HGF/MET Signaling Pathway in Gastric Cancer
Katia De Marco, Martina Lepore Signorile, Elisabetta Di Nicola, Paola Sanese, Candida Fasano, Giovanna Forte, Vittoria Disciglio, Antonino Pantaleo, Greta Varchi, Alberto Del Rio, Valentina Grossi, Cristiano Simone
Cells.2023; 12(20): 2481. CrossRef
MET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver metastasis
Han S. Kim, Hong J. Chon, Hyunki Kim, Su‐Jin Shin, Volker Wacheck, Aaron M. Gruver, Jong S. Kim, Sun Y. Rha, Hyun C. Chung
Journal of Surgical Oncology.2018; 117(8): 1679. CrossRef
Hepatocyte growth factor induced up-regulations of VEGF through Egr-1 in hepatocellular carcinoma cells
Kyung Hee Lee, Jae-Ryong Kim
Clinical & Experimental Metastasis.2009; 26(7): 685. CrossRef
Association of Extracellular Cleavage of E-Cadherin Mediated by MMP-7 with HGF-Induced in vitro Invasion in Human Stomach Cancer Cells
K.H. Lee, E.Y. Choi, M.S. Hyun, B.I. Jang, T.N. Kim, S.W. Kim, S.K. Song, J.H. Kim, J.-R. Kim
European Surgical Research.2007; 39(4): 208. CrossRef

4,413 View
29 Download
7 Crossref

First
Prev
Page of 1
Next
Last

Search